Page 80 - 《中国药科大学学报》2026年第2期

学报
206 Journal of China Pharmaceutical University 2026, 57(2): 206 − 214

胰腺癌靶向纳米载体的合成、表征及其改善光动力治疗研究

乔佳男 1,2,3* ，田烽椿 3

（ 南京中医药大学附属中西医结合医院, 南京 210028； 江苏省中医药研究院, 中药组分与微生态研究中心, 南京 210028；
2
1
中国药科大学药学院, 南京 211198）
3
摘 要 采用点击化学方法合成了一种胰腺癌靶向纳米载体 LL-PTP，物理包载难溶性光敏药物酞菁锌（ZnPc）制备成 LL-
PTP/ZnPc 纳米粒。LL-PTP 临界聚集浓度为 52.97 μg/mL，物理包载 ZnPc 形成的 LL-PTP/ZnPc 纳米粒为蓝色透明溶液，
ZnPc 载药量为（20.1±1.4）%，水合粒径为（89.18±0.21）nm，具有良好的放置稳定性和血清稳定性，符合临床对注射剂型稳
定性的要求，并且 LL-PTP/ZnPc 在肿瘤组织中释药比例可达到血清中的 6 倍以上，有利于纳米粒在肿瘤组织中发挥治疗作
用。分别经激光共聚焦显微镜和流式细胞术进行定性和定量研究 LL-PTP/ZnPc 靶向摄取行为，结果表明，LL-PTP/ZnPc 通
过 Plectin-1 介导的胞吞作用增加 PANC-1 细胞对纳米粒摄取，效率显著优于 LL/ZnPc 和游离 ZnPc。探针 DCFH-DA 检测胞
内 ROS 水平结果显示，光照 LL-PTP/ZnPc 诱导胞内 ROS 生成，有利于在胰腺癌中发挥更好的光动力治疗作用。综上，本研
究成功制备了胰腺癌靶向纳米载体 LL-PTP，并成功负载 ZnPc，改善其光动力治疗效果。
关键词 胰腺癌；靶向纳米载体；光动力治疗；纳米载体合成；纳米载体表征；光动力治疗增效
中图分类号 R944 文献标志码 A 文章编号 1000−5048(2026)02−0206−09
doi：10.11665/j.issn.1000−5048.2025090601

引用本文 乔佳男，田烽椿. 胰腺癌靶向纳米载体的合成、表征及其改善光动力治疗研究 [J]. 中国药科大学学报，2026，57（2）：206-214.

Cite this article as: QIAO Jianan, TIAN Fengchun. Synthesis, characterization and application of targeted nanocarrier improving
photodynamic therapy for pancreatic cancer[J]. J China Pharm Univ, 2026, 57(2): 206-214.

Synthesis, characterization and application of targeted nanocarrier improving
photodynamic therapy for pancreatic cancer
QIAO Jianan 1,2,3* , TIAN Fengchun 3
1
Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing
2
210028; Research Center for Microecology of Functional Components in Traditional Chinese Medicines, Jiangsu Provincial
3
Academy of Chinese Medicine, Nanjing 210028; School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

Abstract LL-PTP, a pancreatic cancer-targeted nanocarrier, was synthesized via click chemistry, and the
insoluble photosensitive drug zinc phthalocyanine (ZnPc) was physically encapsulated within LL-PTP to
fabricate LL-PTP/ZnPc nanoparticles. The critical aggregation concentration (CAC) of LL-PTP was determined
to be 52.97 μg/mL; the LL-PTP/ZnPc nanoparticles, formed by the physical encapsulation of ZnPc, appeared as a
blue transparent solution; the ZnPc loading efficiency of these nanoparticles was (20.1 ± 1.4) %, with a hydrated
particle size of (89.18 ± 0.21) nm; notably, the nanoparticles exhibited excellent storage stability and serum
stability, which fully meet the stability requirements for injectable formulations in clinical applications;
furthermore, the release rate of LL-PTP/ZnPc in tumor tissue was significantly higher (6.2-fold) than that in
serum, which is significantly beneficial for the therapeutic effect of nanoparticles at the tumor site. To investigate
the targeted uptake of LL-PTP/ZnPc, qualitative and quantitative analyses were performed using confocal laser
scanning microscopy (CLSM) and flow cytometry, respectively, with the result that LL-PTP/ZnPc enhanced the
uptake of nanoparticles by PANC-1 cells (a pancreatic cancer cell line) through Plectin-1-mediated endocytosis

收稿日期 2025-09-06 * 通信作者 E-mail：764579493@qq.com
基金项目 国家自然科学基金项目（No. 82404550）；江苏省自然科学基金项目（BK20221044）